14:50:20 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-25 Bokslutskommuniké 2024
2024-11-20 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-22 X-dag ordinarie utdelning SYNT 0.00 SEK
2024-05-21 Årsstämma 2024
2024-05-21 Kvartalsrapport 2024-Q1
2024-02-20 Bokslutskommuniké 2023
2024-02-20 Extra Bolagsstämma 2024
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-22 Kvartalsrapport 2023-Q2
2023-05-24 X-dag ordinarie utdelning SYNT 0.00 SEK
2023-05-23 Årsstämma 2023
2023-05-23 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-11 X-dag ordinarie utdelning SYNT 0.00 SEK
2022-05-10 Kvartalsrapport 2022-Q1
2022-05-10 Årsstämma 2022
2022-03-29 Extra Bolagsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-05-20 Split SYNT 1:10
2021-05-12 X-dag ordinarie utdelning SYNT 0.00 SEK
2021-05-11 Kvartalsrapport 2021-Q1
2021-05-11 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-10-02 X-dag ordinarie utdelning SYNT 1.50 SEK
2020-07-14 Kvartalsrapport 2020-Q2
2020-05-05 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-07-14 Kvartalsrapport 2019-Q2
2019-04-30 X-dag ordinarie utdelning SYNT 1.50 SEK
2019-04-29 Kvartalsrapport 2019-Q1
2019-04-29 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-16 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-04-26 X-dag ordinarie utdelning SYNT 0.00 SEK
2018-04-25 Kvartalsrapport 2018-Q1
2018-04-25 Årsstämma 2018
2018-02-21 Bokslutskommuniké 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-26 X-dag ordinarie utdelning SYNT 0.00 SEK
2017-04-25 Årsstämma 2017
2017-04-25 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-10-28 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-04-27 X-dag ordinarie utdelning SYNT 0.00 SEK
2016-04-26 Årsstämma 2016
2016-04-26 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-04-13 Årsstämma 2015
2015-04-13 Kvartalsrapport 2015-Q1
2015-02-17 X-dag ordinarie utdelning SYNT 0.00 SEK
2015-02-13 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-09-26 Extra Bolagsstämma 2014
2014-08-29 Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
SyntheticMR är ett medicinteknik-bolag som är verksamt inom utveckling av analys - och avbildningsmetoder. Tekniken används huvudsakligen för magnetisk resonanstomografi (MR) inom sjukvården. Tekniken baseras på kvantifieringsbaserad metod som ämnar öka effektiviteten och kvalitén i nuvarande MR-undersökningar. Bolaget etablerades under 2007 och har sitt huvudkontor i Linköping.
2024-06-26 13:30:00

SyntheticMR announced today that version 15 of their next-generation imaging solution, SyMRI Neuro, has obtained CE-marking. 

[image]

SyMRI 15  is a cutting-edge imaging solution set to transform the medical imaging landscape with a host of innovative applications integrated into SyMRI's post-processing suite. In addition to the  previously communicated launch of SyMRI 3D (14), the reinforced solution now include images that are proven to have the same capability as conventional for diagnostic purpose and thereby offer even more value from same sequence.

SyMRI 15 has been clinically proven and validated in a large multi-center study across several high-profile institutes in the United States. The results of the clinical study showed that SyMRI 3D can replace conventional 3D images, enhancing both efficiency and throughput. This is in addition to its established capabilities in providing quantitative values and tissue segmentation. The findings reinforce its diagnostic accuracy, instilling confidence in SyMRI users to substitute conventional 3D images with SyMRI T1 and T2 images.

With the introduction of SyMRI 15, we are also unveiling tools for efficient patient monitoring, alongside providing contrast-weighted images and quantitative information. This technique empowers clinicians with deeper insights into patient health, enabling improved patient care by facilitating a more comprehensive understanding of pathological changes and treatment effects over time.

"We are thrilled to announce that Version 15 of our 3D SyMRI solution is now CE-marked," says Ulrik Harrysson, CEO of SyntheticMR AB. "This next generation of SyMRI 3D delivers unparalleled resolution and accuracy in brain imaging, transforming the field of medical diagnostics."

SyntheticMR has an exclusive agreement with Philips Healthcare for the distribution of SyMRI 15. This agreement between Philips and SyntheticMR means that SyMRI 3D will be included in Philips' global price book and enable Philips to offer the complete package to their customers.

The CE mark qualification for SyMRI 3D signifies a monumental stride for SyntheticMR, reaffirming its commitment to transforming medical imaging on a global level. 

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-06-2024 13:30 CET.